# A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

> **NCT06413498** · PHASE3 · RECRUITING · sponsor: **Kite, A Gilead Company** · enrollment: 450 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Anitocabtagene Autoleucel
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Pomalidomide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT06413498
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-23
- **Primary completion:** 2028-07
- **Final completion:** 2031-07
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413498, "A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06413498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*